PAR 0.00% 29.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4100

  1. 3,957 Posts.
    lightbulb Created with Sketch. 1372
    Efficacy and safety of pentosan polysulfate sodium in people with symptomatic knee osteoarthritis and dyslipidaemia: protocol of the MaRVeL trial
    https://pubmed.ncbi.nlm.nih.gov/38777590/

    ACTRN12621000654853
    A Double-Blind, RandoMised, Placebo-Controlled Study to Assess the
    Efficacy and Safety of oRal deliVery of sodium Pentosan Polysulfate (PPS)
    compared to placebo in participants with symptomatic kneE osteoarthritis
    (OA) and dysLipidemia (MaRVeL Study)

    https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000654853

    Name
    Arthropharm Pty Ltd
    https://www.arthropharm.com.au/
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
0.000(0.00%)
Mkt cap ! $103.1M
Open High Low Value Volume
29.0¢ 29.5¢ 27.5¢ $167.1K 590.3K

Buyers (Bids)

No. Vol. Price($)
2 24553 29.0¢
 

Sellers (Offers)

Price($) Vol. No.
29.5¢ 49999 1
View Market Depth
Last trade - 16.10pm 04/07/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.